8 months ago
FDA Approves Novo Nordisk's Wegovy Pill
Novo Nordisk, a big medicine company from Denmark, got permission from the US FDA to sell a new weight loss pill called Wegovy.
This news made their stock price go up by more than 7%.
The pill is supposed to help people lose weight and keep it off, and it's also good for their heart.
Novo Nordisk plans to start selling the pill in the US early next year.
Their stock has been doing well over the last five years, but it went down a lot in the last year.
The company is also asking other places, like Europe, to approve the pill too.
The pill is taken once a day on an empty stomach and has shown good results in helping people lose weight.
Some people might feel sick to their stomach, but it's not very common.
Novo Nordisk's stock price jumped over 7% after FDA approval of the Wegovy pill on 22 December 2025.
The Wegovy pill is a once-daily medication aimed at reducing excess body weight and cardiovascular risks.
Novo Nordisk plans to launch the Wegovy pill in the US by early January 2026.
The company's stock has seen a 52% increase over five years but a 47.68% decrease over the past year.
Novo Nordisk has submitted the Wegovy pill for approval to the European Medicines Agency (EMA) and other regulatory authorities.
- Who
- Novo Nordisk, a Denmark-based pharmaceutical company
- What
- Received FDA approval for the Wegovy pill, a weight loss drug
- Where
- United States
- When
- 22 December 2025
- Why
- To provide a convenient, once-daily pill for weight loss and cardiovascular risk reduction
Key facts
- Company
- Novo Nordisk
- Stock Price Increase
- 7.18%
- Current Stock Price (DKK)
- 325.30
- Previous Close (DKK)
- 303.50
- Market Capitalization (DKK)
- 1.35 trillion
- Market Capitalization (USD)
- $211.7 billion
- 52-Week High (DKK)
- 675.20
- 52-Week Low (DKK)
- 266.90
- 5-Year Returns
- 52%
- 1-Year Returns
- -47.68%
- 1-Month Returns
- 13.50%
- 5-Day Returns
- 6%
- ADR Stock Price (USD)
- $51.29
- Previous ADR Close (USD)
- $48.10
- Approval Date
- 22 December 2025
- Expected Launch Date (US)
- Early January 2026
- Regulatory Submissions
- EMA and other authorities (H2 2025)
- Active Ingredient
- Semaglutide
- Dosage Forms
- 1.5mg, 4mg, 9mg, 25mg
- Initial Dose Cost
- $149
- Weight Loss (Highest Dose)
- 16.6%
- Clinical Trial Duration
- 64 weeks
- Side Effects
- Nausea, vomiting, gastrointestinal issues
Quotes
Dr Christopher McGowan
Gastroenterologist with a weight loss clinic in Cary, North Carolina
“This is a meaningful step forward in the field. It won’t replace injectables, but it broadens our tool kit in an important way.”
firstpost.com
“Pills are familiar, nonintimidating and fit more naturally into most people’s routines. For many patients, a pill isn’t just easier, it’s psychologically more acceptable.”
firstpost.com
Dr Jason Brett
Principal US medical head for Novo Nordisk
“The Wegovy pill will be available in doses of 1.5 milligrams, four milligrams, nine milligrams and the likely longer-term dose of 25 milligrams.”
firstpost.com
David Moore
Executive vice president of Novo Nordisk’s US operations
“We now have injectable-like efficacy in a once-daily pill. And that’s a change from where we’ve been in terms of treating obesity.”
firstpost.com
Sources
Novo Nordisk jumped 9% in a single day. Here’s the pill that did it.
No injections needed! FDA approves THIS ‘once-daily’ oral weight loss pill – All you need to know
Novo Nordisk stock jumps over 7% after weight loss drug Wegovy pill gets US FDA nod — Details here
A pill a day to keep obesity away?
Related news
EU Plans Greenland Investment Boost Amid Trump Control Push
Denmark Plans First Migrant Returns to Non-EU Hub
Actors Challenge UK Government Over AI Voice Protection Laws
Denmark Says Russia Recruits Danes for Sabotage Planning
Denmark Sends Conscripts to Greenland as Arctic Tensions Rise
